Clear answers for careful participation.

MDA helps people affected by mitochondrial disease learn about research participation, community programs, consent choices, and ways to support discovery.

No. Mito Discovery Alliance is the public website and community doorway. Mito Map is the secure profile tool where patients can organize health information, manage consent choices, and review research opportunities.

No. You can read the site, attend public events, subscribe, and create a basic MDA account without Mito Map. Mito Map is useful later if you want private profile tools, detailed consent choices, or study matching.

Yes. You can begin with the public explanation, join for free, and stop there until you are ready to share more. Detailed health records, consent choices, and patient-level matching stay in Mito Map.

MDA does not generate personalized recommendations on the public site. If you later use Mito Map, it can help you see what to update next, what changed since your last visit, and which research opportunities may be worth reviewing. Those suggestions stay in Mito Map and are not a diagnosis, treatment plan, or personal forecast for one person.

Start with the basics, then use Mito Map later only if you want private health details, consent choices, or a clearer summary for visits. Come back when symptoms, care, or goals change so your next summary stays current.

Most people can create an Alliance account in a few minutes. You only need a name, email, and password to start; any program-specific questions come later if they are actually needed.

No. Joining MDA stays free. If an activity later offers credits or approved Patient Success payments, you review that opportunity separately before you decide whether to take part.

No. You can begin with the public explanation and a basic account. Medical records, genetic reports, or detailed history are only requested when a program or research pathway truly requires them and the page says so first.

The public website collects information people choose to submit, such as contact forms, event interest, story submissions, newsletter requests, and program participation details. Detailed health records are kept in Mito Map or other approved study systems when a member chooses to use them.

Identifiable patient records are not sold through the public MDA website. Any research or partner use is explained in plain language and depends on the appropriate consent and review process.

A clinician referral should stay lightweight: enough information for follow-up, but not raw charts, genetic reports, or urgent clinical detail. The patient still decides whether to continue.

They can review the public explanation, learn how privacy and consent work, and decide whether to join the Alliance or create a Mito Map profile for selected summaries and research opportunities.

It is a short downloadable summary that gives clinic teams the fastest read on MDA, the MDA/Mito Map boundary, what to share, and what to avoid sending. It is meant for education and referral support, not medical advice.

Clinicians can start with the handout for a patient-friendly overview, then open the quick-start one-pager if they want the boundary and follow-up language in a shorter format. Patients who want a take-home prompt for clinic can use the patient visit summary template to note what changed and what they want to ask next.

It is a short patient-controlled note for what changed, what to ask, and what should stay private before a visit. It helps families organize the story without copying raw charts or lab files into public forms.

If you use Mito Map, you can keep a current summary, timeline, and notes in one place so it is easier to bring a short overview to visits, reduce repeat retelling, and focus on the questions that matter most. Bring the questions you want answered and note what changed since the last visit. MDA is educational and does not give medical advice.

Bring a short list of what changed, the questions you want answered, and any current summary you already use. If you use Mito Map, bring the latest summary instead of rebuilding the story from memory. Keep full records and urgent questions out of the public forms.

Returning with updates after symptoms, care, or goals change helps your summary stay current in Mito Map and gives the community a clearer picture of how mitochondrial disease changes over time. MDA only uses aggregate, reviewed information on the public site, so you stay in control of what you share.

Yes. Members can review specific research opportunities and choose whether to opt in, decline, or withdraw where the study rules allow.

You can change future participation choices where feasible. Some completed analyses may not be reversible, so each opportunity explains the limits before you decide.

People with confirmed mitochondrial disease, people with suspected mitochondrial conditions, caregivers, family members, and non-mito comparison volunteers may be eligible. Individual programs may add location, age, or diagnosis details, and the page will say so before you apply.

Yes. Caregivers can help a loved one understand the Alliance, support profile completion, attend events, and participate where program rules allow.

No. MDA is not a medical provider and does not provide medical advice, diagnosis, treatment, or emergency support.

Clinicians can share MDA when a patient or caregiver wants to learn about research participation, organize their story, or stay informed about mitochondrial disease programs without adding new clinical administration.

Patients can get paid through eligible MDA programs. Some activities earn participation credits, and approved Patient Success distributions may pay patients when qualifying value exists. Payments are not guaranteed, are subject to program rules, eligibility, approval, and available qualifying value, and are not investment returns, dividends, equity, or guaranteed payments.

Credits are a record of eligible participation activity inside Alliance programs. They may be used to support payment eligibility review for approved Patient Success distributions, but they are not cash, equity, tokens, a discount, or a promise of future payment.

MDA uses the same published rules for everyone. You can say no to one request and still remain part of the community where program rules allow, and any approved payment or distribution is reviewed against the same eligibility window, available qualifying value, and governance rules. Participation credits are not a ranking of who matters more.

Research and partner requests are reviewed for purpose, privacy, consent requirements, participant burden, conflicts of interest, and expected value back to the patient community.

When people can see what is being asked and join in a clear, consented way, researchers can design better studies, compare aggregate patterns more cleanly, publish clearer reports, and return plain-language findings when results are ready.

When people choose to share updated summaries over time, the system can compare current, consent-aware data instead of relying on one old snapshot. That can make aggregate AI models, prediction checks, cohort readiness review, and follow-up prompts more current, but it does not create a diagnosis, treatment plan, or guaranteed prediction for one person.

It does not guarantee approval. But when people join, keep consent current, and share updated summaries, MDA can return reviewed aggregate evidence to researchers and approved sponsors. That helps them design better studies, see real-world patterns, and decide what is worth advancing. Detailed health data stays in Mito Map.

General contact messages are reviewed by the community manager first, and most are reviewed within 2 business days. If your note fits another page, using the closest page first helps it reach the right owner faster.

Reviewed publications, presentations, research milestones, and plain-language findings are shared on the Impact page when they are ready for the community.